A new drug offers significant advantages over existing treatments for type 2 diabetes patients who do not respond to metformin, suggest findings from a trial in the Lancet online.
Treatment with Linagliptin (Tradjenta) resulted in significantly less weight gain than a commonly-used second-line treatment, the sulphonylurea glimepiride, and may carry a smaller risk of cardiovascular events, according to researchers from Tübingen University Hospital in Germany and the drug’s manufacturer Boehringer Ingelheim.
The two-year trial compared linagliptin with glimepiride in more than 1,500 diabetes patients from 16 countries.
Lead author Professor Baptist Gallwitz said: “Since hypoglycaemia can have substantial negative clinical consequences in terms of cognitive function, mortality, morbidity, adherence to treatment, and quality of life, its prevention is a crucial component of any diabetes management programme.”
The trial results are published online in the Lancet.